在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

CRKL Antibody

  • 中文名稱:
    CRKL兔多克隆抗體
  • 貨號:
    CSB-PA129519
  • 規格:
    ¥1100
  • 圖片:
    • The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using CSB-PA129519(CRKL Antibody) at dilution 1/25, on the right is treated with synthetic peptide. (Original magnification: ×200)
    • The image on the left is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using CSB-PA129519(CRKL Antibody) at dilution 1/25, on the right is treated with synthetic peptide. (Original magnification: ×200)
    • Gel: 15%SDS-PAGE, Lysate: 40 μg, Lane 1-3: Lovo cells, Raji cells, A172 cells, Primary antibody: CSB-PA129519(CRKL Antibody) at dilution 1/600, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute
  • 其他:

產品詳情

  • Uniprot No.:
  • 基因名:
  • 別名:
    Crk L antibody; Crk like protein antibody; Crk-like protein antibody; Crkl antibody; CRKL_HUMAN antibody; Crkol antibody; HGNC:2363 antibody; Oncogene CrkL antibody; V crk avian sarcoma virus CT10 oncogene homolog like antibody; v crk sarcoma virus CT10 oncogene homolog (avian) like antibody; V crk sarcoma virus CT10 oncogene homolog avian like antibody
  • 宿主:
    Rabbit
  • 反應種屬:
    Human,Mouse,Rat
  • 免疫原:
    Synthetic peptide of Human CRKL
  • 免疫原種屬:
    Homo sapiens (Human)
  • 標記方式:
    Non-conjugated
  • 抗體亞型:
    IgG
  • 純化方式:
    Antigen affinity purification
  • 濃度:
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液:
    -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
  • 產品提供形式:
    Liquid
  • 應用范圍:
    ELISA,WB,IHC
  • 推薦稀釋比:
    Application Recommended Dilution
    ELISA 1:2000-1:5000
    WB 1:500-1:2000
    IHC 1:25-1:100
  • Protocols:
  • 儲存條件:
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期:
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
  • 用途:
    For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

  • 功能:
    May mediate the transduction of intracellular signals.
  • 基因功能參考文獻:
    1. Taken together, our data demonstrated that miR-429 might function as an antimetastatic miRNA to regulate HCC metastasis by directly targeting CRKL via modulating Raf/MEK/ERK-epithelial mesenchymal transition pathway. PMID: 29403024
    2. High CRKL expression is associated with Cervical Cancer. PMID: 29295725
    3. Silencing CRKL expression in PTEN-null human cancer cells leads to a decrease in p110beta-dependent PI3K signaling and cell proliferation. PMID: 28723560
    4. Study found the expression of CRKL up-regulated and correlated with that of ABCG2 in gastric neoplasm. CRKL is one of the downstream molecules regulated by ABCG2, which promotes cell growth. PMID: 28029654
    5. We demonstrated that CRKL is a novel downstream effector of ALK signaling in non-small-cell lung cancer PMID: 27078848
    6. Dynamic multi-site phosphorylation by Fyn and Abl drives the interaction between CRKL and the novel scaffolding receptors DCBLD1 and DCBLD2. PMID: 29025973
    7. Data show that miR-193b, by directly targeting focal adhesion kinase (FAK), CRK-like proto-oncogene (CRKL), and methionine sulfoxide reductase A (MSRA), regulates focal adhesion signaling and ROS signaling, which play pivotal roles in liposarcomagenesis and adipogenic differentiation. PMID: 28882999
    8. TP53-miR-215-PCAT-1-CRKL axis might represent an important regulatory pathway in hepatocellular carcinoma. PMID: 28887306
    9. The impaired T-cell proliferation and reduction of CRKL, phosphorylated CRKL, and c-Fos levels suggest a possible role of CRKL in functional deficiencies of T cells in patients with pDGS. PMID: 26875746
    10. he findings in this study indicate a regulation relationship between CRKL and SLC7A5, and provide useful evidence for gastric cancer therapeutic strategies. PMID: 27846244
    11. We identified a recurrent 370-kb deletion at the 22q11.2 locus as a driver of kidney defects in the DiGeorge syndrome and in sporadic congenital kidney and urinary tract anomalies. SNAP29, AIFM3, and CRKL appear to be critical to the phenotype, with haploinsufficiency of CRKL emerging as the main genetic driver. PMID: 28121514
    12. a role for miR-429 as a novel target suppressing invasion and migration of human cervical cancer cells through modulation of its targeting genes ZEB1 and CRKL, is reported. PMID: 27133071
    13. CrkL mediates CCL20/CCR6-induced epithelial-to-mesenchymal transition via Akt pathway, instead of Erk1/2 pathway in development of gastric cancer PMID: 26044596
    14. CrkL regulates CCL19 and CCR7-induced epithelial-to-mesenchymal transition via ERK signaling pathway in epithelial ovarian carcinoma patients. PMID: 25636509
    15. these results suggest that CrkL plays a regulatory role in the SDF-1-induced Erk1/2 and PI3K/Akt pathways and further managed the invasion and migration of breast cancer cells PMID: 25476480
    16. The authors show that this potentiation involves reorganization of the natural CrkL-p85beta complex into a novel trimeric complex where influenza A virus NS1 serves as a bridging factor. PMID: 26099693
    17. Our results demonstrate that the p53 target miR-200b/200c/429 miRNAs are negative regulators of the CRKL oncogene PMID: 26079153
    18. results suggested that overexpression of CRKL promoted cell invasion through upregulation of MMP9 expression and activation of ERK pathway PMID: 24664993
    19. CRKL has the potential to be used as a biomarker for the diagnosis, treatment and prognosis of certain tumors PMID: 25531052
    20. We identified ZEB1 and CRKL as potential targets of miR-429 by analyzing combined results from in silico search and global expression array of the same RNA samples. Immunoblot assay confirmed that miR-429 reduced their expression at protein level. PMID: 25405387
    21. These results indicate that CRKL gene amplification is rare in acquisition of resistance to EGFR-TKIs in lung cancer patients with EGFR mutations. PMID: 24939008
    22. CrkL knockdown markedly suppressed the phosphorylated ERK (p-ERK) as well as the phosphorylated AKT (p-AKT) (p < 0.001) compared with control or TGF-b1 alone. PMID: 25307974
    23. our study demonstrated that CRKL was overexpressed in human pancreatic cancers and contributed to pancreatic cancer cell proliferation and invasion through ERK signaling. PMID: 25318601
    24. Study revealed that LASP1 phosphorylation results in an association with CRKL - another specific BCR-ABL substrate and bona fide biomarker for BCR-ABL activity. PMID: 24913448
    25. Haploinsufficiency of CRKL could be responsible for the etiology of conotruncal heart defects in individuals with nested distal deletions and might act as a genetic modifier of individuals with the typical 3 Mb deletion. PMID: 25658046
    26. CrkL is highly expressed in papillary thyroid carcinoma and papillary thyroid microcarcinoma and closely correlated to metastasis. PMID: 25185652
    27. results suggest that CRKL has the ability to regulate colon cancer malignancy and CRKL has the potential to serve as a diagnosis and prognosis marker and a therapy target of colon cancer PMID: 24389200
    28. CRKL is overexpressed in bladder cancer and regulates malignant cell growth and invasion. PMID: 24375195
    29. This is the first report to elucidate the novel function of NS1--binding protein collaborating with viral protein NS1 in modulation of host cell physiology. In addition, an alternative role of adaptor protein CRKL in association with NS1 and NS1-BP during influenza A virus infection is demonstrated. PMID: 24220336
    30. Data show Src-inducible association of CrkL with procaspase-8 promotes cell migration. PMID: 23751956
    31. CRKL may recruit NleH1 to a host kinase on which NleH1 performs its inhibitory function. PMID: 24145029
    32. we identified CRKL/YES as critical interrelated pathways necessary for rhabdomyosarcoma cell growth and survival and suggest a potential therapeutic role of SRC family kinase inhibition in the treatment of rhabdomyosarcoma. PMID: 23318429
    33. Knock-down of CRKL in SGC-7901 cells induced a suppression of cell proliferation along with a significant arrest of cell cycle in G0/G1 phase. PMID: 24055140
    34. Overexpression of CRKL in HBE and H1299 cell lines promoted cell proliferation by facilitating cell cycle progression. PMID: 22753141
    35. High expression levels of the CRKL and CRKL-FLT1 pair strongly correlate with reduced disease-free and overall survival in HCC patient samples. PMID: 23397142
    36. Overexpression of CRKL correlated with progression and malignant proliferation of human breast cancers. PMID: 23686806
    37. SFK activity was shown to be sufficient, but not required for the interaction between ESDN and the CrkL-SH2 domain PMID: 23770091
    38. study reveals a significant association between Crk protein expression with highly proliferative tumors and basal breast cancers of poor outcome; data highlight the physiological importance of Crk proteins in regulating growth of aggressive basal breast cancer cells PMID: 22569336
    39. BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response PMID: 22233112
    40. Stathmin and CrkL proteins may be involved in drug resistance of K562 cells to adriamycin. PMID: 22169288
    41. CRKL overexpression induces cell transformation. PMID: 22586683
    42. These results suggested that CRKL protein is overexpressed in a subset of gastric cancers and is associated with CRKL amplification in gastric cancer. PMID: 22591714
    43. In silico three-dimensional modeling of apoptin, molecular docking experiments between apoptin model and the known structure of Bcr-Abl, and the 3D structures of SH2 domains of CrkL and Bcr-Abl, were performed. PMID: 22253690
    44. these results indicate that CRKL regulates HNSCC-cell growth, motility, and integrin-dependent cell adhesion, suggesting that CRKL plays a principal role in HNSCC tumorigenicity. PMID: 22244889
    45. The molecular signaling set off by ERalpha and CrkL association may have a central role in pregnancy and cancer. PMID: 21700719
    46. Lyn controls spatial activation of Rap1 by recruiting the CrkL-C3G protein complex to the leading edge PMID: 21628423
    47. These results suggest that CRKL, but not MAPK1 is the target oncogene of the rare but recurrent amplification at 22q11.2 in laryngeal squamous cell carcinoma. PMID: 21896986
    48. Findings indicate that amplification and resultant overexpression of CRKL contribute to diverse oncogenic phenotypes in lung cancer. PMID: 19966867
    49. DOCK2 associates with CrkL and regulates Rac1 in human leukemia cell lines PMID: 12393632
    50. directs ASAP1 to peripheral focal adhesions in platelets PMID: 12522101

    顯示更多

    收起更多

  • 蛋白家族:
    CRK family
  • 數據庫鏈接:

    HGNC: 2363

    OMIM: 602007

    KEGG: hsa:1399

    STRING: 9606.ENSP00000346300

    UniGene: Hs.5613



主站蜘蛛池模板: 国产精品免费久久久久软件| 日韩欧美亚洲综合久久影院d3| 双乳被一左一右吃着动态图| 免费国产线观看免费观看| 国产精品综合色区在线观看| 久久九九av免费精品| 亚 洲 成 人 网站在线观看| 欲色欲色天天天www| 韩国日本三级在线观看| 国产无线乱码一区二三区| 国精品午夜福利视频| 少妇午夜av一区| 久久久精品国产免大香伊| 日韩精品久久久肉伦网站| 欧美最猛性xxxxx大叫| 久久久久久久久久久综合日本| 国产亚洲精品久久久久久青梅| 人人妻人人澡人人爽人人精品av| 呻吟国产av久久一区二区| 西欧free性满足hd| 国精产品一区一区三区mba下载| 老太脱裤子让老头玩xxxxx| 国产美女精品自在线拍免费| 无码a∨高潮抽搐流白浆| 亚洲欧洲中文日韩久久av乱码| 无码少妇a片一区二区三区| av无码一区二区二三区1区6区| 三级做爰高清视频| 日韩人妻无码精品久久久不卡| 中文在线а√天堂官网| 一色屋精品视频在线观看免费| 国产欧美日韩精品丝袜高跟鞋| 麻麻张开腿让我爽了一夜| 成人亚洲a片v一区二区三区日本| av区无码字幕中文色| 内射爽无广熟女亚洲| 国产激情视频一区二区三区| 欧美乱大交aaaa片if| 男女18禁啪啪无遮挡激烈网站| 国产超碰人人爽人人做| 无码国内精品久久人妻蜜桃|